abiraterone: Clinical Trials

70 trials of abiraterone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 15 recruiting, 10 active not recruiting, 8 terminated. 70 Phase 2, 14 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 270Completed 24, Recruiting 15, Active not recruiting 10, Terminated 8, Unknown 6, Not yet recruiting 3, Withdrawn 3, Suspended 1
Phase 114Completed 4, Recruiting 4, Terminated 3, Unknown 2, Active not recruiting 1
Phase 34Active not recruiting 2, Completed 1, Not yet recruiting 1

Follow abiraterone: new trials by email Literature Review of abiraterone trials Research Report on abiraterone

Trials (filtered) newest first · largest first

All 70 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.
ADT plus abiraterone or other ARPIs(apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer
Phase 2Not yet recruitingAnhui Medical University402026-10-012026-08-31
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer
Phase 2RecruitingUniversity of Nebraska1402026-09-012026-10-19
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer
Phase 2 / Phase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.1802026-09-012026-07-23
Study of XNW5004 Tablets in Advanced Prostate Cancer
XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer
Phase 2Not yet recruitingEvopoint Biosciences Inc.2422026-07-132026-07-28
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Inavolisib, Enzalutamide, Abiraterone - Metastatic Castration-Resistant Prostate Cancer
Phase 2RecruitingHoffmann-La Roche1002026-03-112026-11-06
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals1812026-01-132026-11-13
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet - Prostate Cancer
Phase 2RecruitingJiangsu HengRui Medicine Co., Ltd.2182025-12-082026-03-03
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals1232025-12-052026-10-15
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
Abiraterone 250 mg with food + prednisone - Prostate Cancer (Diagnosis)
Phase 2RecruitingSMED Clinical Research602025-12-012025-12-23
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Abivertinib, Abiraterone - Prostate Cancer, Prostate Cancer Metastatic
Phase 2SuspendedSorrento Therapeutics, Inc.1002025-09-012024-03-18
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease
Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine1922025-08-012026-03-25
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II Study
Disitamab Vedotin (RC48), Abiraterone + prednisone - mCRPC
Phase 2RecruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School202025-07-202025-07-30
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
JSB462, Abiraterone, Enzalutamide - Metastatic Hormone-sensitive Prostate Cancer
Phase 2Active not recruitingNovartis Pharmaceuticals1682025-07-072026-11-13
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC3602025-07-032026-10-09
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C) - High Risk Prostate Carcinoma, Prostate Cancer
Phase 2Active not recruitingIvan de Kouchkovsky, MD322024-12-092026-09-04
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg - Metastatic Castration-resistant Prostate Cancer
Phase 2Active not recruitingR-Pharm International, LLC1202024-10-242026-04-28
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Phase 2RecruitingMayo Clinic5322024-06-032026-07-20
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment - Metastatic Hormone-Sensitive Prostate Cancer
Phase 2UnknownJianbin Bi1602023-11-152023-11-18
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Abiraterone, Biospecimen Collection, Darolutamide - Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 2RecruitingUniversity of California, Davis752023-11-092026-03-13
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Docetaxel, ADT, Abiraterone - Prostate Cancer
Phase 2WithdrawnNorthwestern University2023-10-192025-10-22

Showing 20 of 70. Sign in to see all of them.

Conditions studied

Prostatic Neoplasms (44)  ·  Prostatic Neoplasms, Castration-Resistant (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Neoplasm Metastasis (3)  ·  Genital Neoplasms, Male (2)  ·  Melanoma (2)  ·  Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Urogenital Neoplasms (2)  ·  Anus Neoplasms (1)  ·  Bites and Stings (1)  ·  Breast Neoplasms (1)  ·  Bulbo-Spinal Atrophy, X-Linked (1)  ·  Carcinoma, Hepatocellular (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  Janssen Research & Development, LLC (3)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Masonic Cancer Center, University of Minnesota (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  National Cancer Institute (NCI) (2)  ·  University Health Network, Toronto (2)  ·  University of Michigan Rogel Cancer Center (2)  ·  VA Office of Research and Development (2)  ·  Amgen (1)  ·  Anhui Medical University (1)  ·  Arno Therapeutics (1)  ·  AstraZeneca (1)  ·  British Columbia Cancer Agency (1)  ·  Cardiff Oncology (1)

Countries

United States (42)  ·  Spain (12)  ·  China (11)  ·  France (10)  ·  Australia (9)  ·  Canada (9)  ·  United Kingdom (9)  ·  Italy (8)  ·  Brazil (6)  ·  Germany (5)  ·  Netherlands (5)  ·  South Korea (5)  ·  Belgium (4)  ·  Poland (4)  ·  Czechia (3)

Top investigators

Jingsong Zhang, MD, PhD (2)  ·  Zachery Reichert, MD, PhD (2)  ·  Abhishek Solanki, MD MS (1)  ·  Albert Font, MD (1)  ·  Anthony Joshua, MD,MBBS,PhD,FRACP (1)  ·  Carmen Santander, MD (1)  ·  Charles Ryan, MD (1)  ·  Dana Rathkopf, MD (1)

Results publications

PMID 18990168, PMID 22452894, PMID 22747660, PMID 25320340, PMID 25425730, PMID 26718929, PMID 26719232, PMID 27068431, PMID 28178640, PMID 28300506, PMID 28578639, PMID 29384722, PMID 29529169, PMID 29723398, PMID 29740894, PMID 30355464, PMID 30686756, PMID 30935383, PMID 31122212, PMID 31527168, PMID 31560068, PMID 32994091, PMID 33270906, PMID 33599706, PMID 33836265, PMID 34646387, PMID 34655838, PMID 34757812, PMID 34953525, PMID 35671327, PMID 36055231, PMID 36059000, PMID 36063830, PMID 36099670, PMID 36210487, PMID 37142371, PMID 37973477, PMID 38824003, PMID 39036382, PMID 39293393, PMID 39643549, PMID 39804646, PMID 39857987, PMID 40177596, PMID 40387589, PMID 40467357, PMID 40539499, PMID 40639383, PMID 40677104, PMID 40693904

NIH funding

2025 (3), 2017 (2), 2004 (1), 2019 (1), I01CX002277 (1), P01CA203628 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), R01CA286127 (1), R01CA300454 (1)